Intravenous β‐lactam antibiotics remain a cornerstone in the management of bacterial
infections due to their broad spectrum of activity and excellent tolerability. β‐lactams are well …

Introduction Continuous infusion (CI) of beta-lactam antibiotics may be of benefit in some
patients, particularly those with severe infections. However, most studies have been small …

The surge in antimicrobial resistance and the limited availability of new antimicrobial drugs
has fueled the interest in optimizing antibiotic dosing. An ideal dosing regimen leads to …

Beta-lactam antibiotics are often the backbone of treatment for Gram-negative infections in
the critically ill. Beta-lactams exhibit time-dependent killing, and their efficacy depends on …

Various studies have reported insufficient beta-lactam concentrations in critically ill patients.
The optimal dosing strategy for beta-lactams in critically ill patients, particularly in septic …

Hospital-acquired pneumonia (HAP) is a leading cause of morbidity and mortality,
commonly caused by Pseudomonas aeruginosa. Meropenem is a commonly used …

We evaluated piperacillin-tazobactam and tobramycin regimens against Pseudomonas
aeruginosa isolates from critically ill patients. Static-concentration time-kill studies (SCTK) …

Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli are a global public-
health concern. We evaluated the pharmacodynamic activity of piperacillin/tazobactam …

Infections caused by multi drug resistant (MDR) gram negative bacteria in critically ill
patients and complex clinical settings present challenges to the selection of appropriate …

We read with interest the article by Sumi et al. 1 about the pharmacodynamic evaluation of
intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow …